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• The authors report on six pediatric liver transplant 
recipients for whom allograft tolerance occurred shortly after 
transplantation (ie, lesl than 1.5 yearl,. All the patients had 
aSlociated life-threatening viral complications. They are cur-
rently immunocompetent. The tolerant state may be related 
to the development of a TH2 cytokine pattern. 
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DEVELOPMENT of a drug-free state has long been an aspiration in transplantation. It is 
particularly desirable in children because they are 
subject to complications secondary to the lifelong 
administration of immunosuppressive agents. We 
report on a small group of pediatric patients who. in 
the presence of life-threatening complications. had 
allograft tolerance shortly after transplantation. The 
immune unresponsiveness appeared to be donor-
specific. They were shown to be otherwise immuno-
competent. 
MATERIALS AND METHODS 
Case Material 
Among our pediatnc transplant population (liver. kidney. intes-
tinal. and pancreatic islet recipients). there were six patients 
(Table I) who had life-threatemng vlfal infections not long after 
transplantation but also had tolerance to their grafts. All the 
patients were liver transplant recIpients. treated with ch-RM~ 
hased immunosuppression. I The age range at the time of transplan-
tation was 0.3 to 1.5 vears. The pnmary disease was biliarv atresia 
(3). neonatal hepatitIS (I). fulminant hepatitis C (I). or ~at"s eve 
syndrome (I). Posttransplant. three of them had one or mo~e 
episodes of acute rejection that requlfed treatment with sterOids. 
and three had no rejection at all. 
The complications that necessitated discontinuation of the 
immunosuppressIOn were Iymphoproliferative disease (PTLD) 
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(n = 5) and severe hepatitis C (n = 2). Patient no. 4 had both 
complications .. Hepatitis was recurrent in one case and acquired 
after transplantation in the other. Immunosuppression was discon-
tinued 0.5 to \.3 years posttransplantation. and. to date (1.3 to 2.8 
years later). it has not been resumed. 
One patient died after retransplantation for hepatitis C. All 
others are alive with the same grafts. PTLD and hepatitis C have 
been controlled successfully in al\ surviving patients. There have 
been no other severe infections. All patients are rejection-free; this 
was demonstrated clinically. biochemically. and histologically. 
Another patient (no. 7. Table I). a l-year-old girl who received a 
liver allograft under FK-506 for biliary atresia. had severe hepatitis 
C 2 years after transplantation. and the immunosuppression was 
withdrawn. She remained rejection-free for 0.9 years. Rejection 
then developed. which required resumption of FK-506. The patient 
still has evidence of active hepatitis C. 
In Vitro Immunologic Studies 
These tests were done to evaluate immune competence. Func-
tional evaluation of T helper cells was performed by measuring the 
ability of peripheral blood lymphocytes (PBL) to proliferate in 
response to nonspecific plant lectins: phytohemagglutinin (PHA). 
concanavalin A (Can A). and alloantigens. Although the "normal" 
range for each test may vary. the response is considered significant 
if the test value is at least 5- to IO-fold higher than the background 
value obtained in the absence of any stimuli. Patients who are 
immunocompromlsed and at high risk for frequent opportunistic 
infections exhibit very low responses to mitogens and alloantigen. 
These low responders may include transplant recipients on high 
doses of immunosuppressive drugs or patients with the human 
immunodeficiency virus. 2 . .1 
The specllic response of recipient PBL to donor alloantigens can 
he tested with one-wav mixed lymphoc'Yte reaction (MLR). whereby 
t:qual numbers of recipient PBL and irradiated donor cells are 
mixed. and proliferation I, assessed hy the incorporation of 
'H·thymidine at day 6 of coculture. Donor-specific hyporeactivity is 
considered when the patient's MLR response to the donor de-
creases in comparison to the pretransplant values. while the 
proliferative responses to other HLA-incompatible donors remain 
high. 
When donor cells are not avaIlable. we use a panel of stimulators 
in the MLR. whIch are homozygous tor class II HlAs. These 
homozygous tvpmg cells (HTC) are selected to represent cells that 
express "self' HlAs. "donor" HLAs. and other HlAs that are 
unrelated to reCipient or donor antigens. Donor-specific hyporeac-
tivity occurs when the proliferative responses of patIent PBL to self 
and donor HTC are similar. and both responses are SIgnificantly 
I,)wer than those ohserved toward unrelated HTCs.' 
Helper T cclls respond to stimuli in vitro and in vivo by 
producing vanous cvtokines. These mediators have an important 
role in the regulation of cell· mediated and humoral immunity. T 
helper cells can be categOrized according to the l'Ytokine profile 
they secrete. It:. THI or TH,,' Cytokrnes produced by the ru l 
subset are involved in allograft rejection and cellular responses to 
viral infections. whereas those secreted by TH2 cells are mainly 
elevated in allen!!c responses and helminth infections. Cytokines 
produced bv one subset mav modulate and antagonize the etfector 
(unction 01 the other suhset. For instance. TH2·like cYlOkines (ie. 
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Table 1. Uver Transplant Recipients Who Had Developed urty Tolerance to Grafts 
Patient Primary Age at 
No. Sex Diagnosis TranSD4ant8tion Immunosuppression 
1 M Biliary atresia 0.6 FK·506. prednisone 
2 F Neonatal hepatitis 0.3 FK·506. prednisone 
3 F Biliary atresia O.S FK·506. prednisone 
4 M Cat's eye 1.5 FK·506. prednisone 
syndrome 
5 M Biliary atresia FK·506. prednisone 
6 F Fulminant FK·506. prednisone 
hepatitis 
7 F Biliary atresia 1.3 FK·50S. prednisone 
Abbreviations: ACR, acute cellular rejection; HCV. hepatitis C virus. 
"Died after retransplantation for hepatitis C. 
elevated levels of interleukin [IL] 4 or 10) may downregulate the 
rn 1 function (secretion of interferon and activation of macro-
phages).b 
Circulating PBL may already express elevated levels of cytokine 
genes. which could be detected by using sensitive molecular probes. 
In addition. PBL respond to in vitro stimuli by a transient 
upregulation of cytokine genes. We evaluated the T helper pheno-
type (rn I \. TH2) in pediatric liver transplant recipients by testing 
cytokine mRNA expression before PHA stimulation (spontane· 
ous) and after 2 hours' exposure to PHA. The studies performed in 
our patients were as follows. 
Mitogen·mduced proliferotion. Mononuclear peripheral blood 
cells from these patients were isolated with Ficoll gradient and 
cultured in tissue-culture media in the presence of either Con A or 
PHA. Proliferation was measured by JH-thymidine uptake. 
Mixed /\mphocyte reaction (MLR). Unidirectional MLR cui· 
tures were set up with normal. unrelated. irradiated lymphocytes In 
J tissue·culture medium. Proliferation was assessed with .1H· 
thymidine. 
Homozvgous rvping assay. In the absence of donor lymphocytes. 
IITC were used as stimulators of the pal1ents' PBL. using the MLR 
protocol described above. Seven different Ow specifics were tested 
with 2 to J HTC. for specificity.-
DetectIOn ot' cwokine gene expression /Jv reverse transcriptase po/v· 
//Ierase cham reaction (RT·PCR). Total RNA was extracted from 
PBL. A known quantity of total RNA was used for cDNA synthesis. 
The latter was used as a template for PCR amplification. The PCR 
products were analyzed by gel electrophoresis. The presence of 
I L-2 .. t, n. and 10 mRNA in the pallents' PBL was tested before and 
2 hours alter PHA stimulation. 
RESULTS 
Five of the tested patients (nos. L 3, 4. 5, and 7) 
had normal Can A- (12.491 to 41.979 cpm) and 
PHA·induced (58.385 to 188.434 cpm) proliferation 
l)f PBL O.l) to 2.6 years after discontinuation of 
immunosuppression. They also had normal ratio of 
MLR to third-party lymphocytes (23.035:88.l11 cpm). 
These results suggest that pediatric liver transplant 
recipients who are off immunosuppression arc immu-
nocompetent. 
In two patients (nos. 1 and 3) in whom HTC assay 
could be performed. the proliferative response to 
Time Posttransplant Total Time Off 
Posttran.plant Until Off Medication Currant 
ACR Medication Iv') Iv') Complication BioPSV 
None 1.2 2.8 PTLO NoACR 
Mild 0.8 2.1 PTLO NoACR 
ACRX2 0.8 2.5 PTLO NoACR 
Multiple 1.3 PTLO.HCV HCV· 
None 1.3 1.3 PTLO NoACR 
None 0.5 2.8 HCV No ACR. 
noHCV 
ACRX2 2 0.9 HCV Mild ACR. 
HCV· 
HTC that presents donor antigens was in the same 
range as those towards stimulators that present self 
HLA-DR antigens. Both self and donor-specific re-
sponses were less than 50% of the responses toward 
an unrelated third-party stimulator. These results 
suggest that donor-specific hyporeactivity was achieved 
in these two patients. 
Three of four tested patients (nos. 2, 3, and 6) 
showed the presence of IL-4, IL-lO and IL-6 mRNA 
before PHA stimulation. After activation, all PBL 
samples (from patients 1, 2, 3, and 6) showed IL-2, 4, 
6, and 10 mRNA. The spontaneous cytokine profile is 
of the TH2 phenotype. An increase of IL-2 mRNA in 
the stimulated samples confirmed the patients' immu-
nocompetence. 
DISCUSSION 
The description of the two-way cell traffic between 
donor and recipient and the development of mixed 
chimerism;·s have exposed previously unrecognized 
mechanisms of tolerance induction in human recipi-
ents of whole organs. particularly of livers. It also led 
to a controlled attempt at reduction of immunosup-
pression at our center. with total withdrawal as the 
goai~ Long-term survivors have been selected for this 
trial. 
To date. three kidney recipients (of living-related 
I-HLA haplotype-matched grafts) and 52 liver recipi-
ents (mean survival time after transplantation, 8 
years) have been enrolled in this study.t') Fifteen liver 
(29%) and two kidney recipients are currently off 
immunosuppression. The remaining patients are 
gradually being weaned. All patients are alive. and 
there have been no graft losses. Eleven patients 
(21 t;f). all liver recipients. have sustained one episode 
of rejection. which responded to resumption of immu-
nosuppression. In three patients. mild rejection was 
not treated and subsided spontaneously. 
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The fact that immunosuppression can be re-
duced 1.11 or stopped8 after transplantation is best 
exemplified in pediatric patients. In them. immuno-
suppression is automatically down-regulated because 
no increase is made to compensate for growth. 
Discontinuation of immunosuppression has been 
practiced in the treatment of life-threatening compli-
cations after transplantation. 12 The treatment usually 
is resumed because of the fear or occurrence of 
rejection. All but one of our seven patients (no. 7) 
exhibited graft tolerance and were immunocompe-
tent. The potential drug independence of liver recipi-
ents has been noted previously,S but it did not occur 
as after transplantation: in our study, the average 
time until drug independence was 0.93 years. The 
early timing of tolerance and the association with 
life-threatening viral infections differentiate these 
patients from those who had the immunosuppression 
withdrawn systematically. 
All the patients were treated with FK-506. Al-
though in experimental animals there was a higher 
incidence of drug-free tolerance induction with FK-
506 than with conventional immunosuppression in-
cluding cyclosporine.13·14 the end result was not drug-
specific; 15.16 in humans. tolerances has been achieved 
with azathioprine or cyclosporine-based cocktail regi-
mens.s We are currently observing a patient treated 
with cyclosporine who is tolerant to her combined 
liver-kidney graft 8 years after transplantation. 
TZAKIS ET AL 
All patients in the present series were solitary liver 
recipients. Although the liver is known to be more 
tolerogenic than the other solid organs.S.16-18 rejection 
remains a threat. as exemplified by case 7. If drug 
weaning is undertaken. the need for careful supervi-
sion and long-term follow-up cannot be overempha-
sized. 
The resting PBL cytokine pattern was negative for 
IL-2 mRNA and positive for IL-4, 6, and 10, suggest-
ing a TH2 cytokine pattern. This dominant TH2-like 
immune response may have facilitated donor-specific 
hyporeactivity and graft acceptance in a drug-free 
environment. 19 A similar TH2 cytokine pattern has 
been seen in liver biopsy specimens from patients 
with PTLD.20 
The emergence of T helper phenotype 2 in liver 
transplant recipients after PTLD or other infections 
requires further consideration. TH2-like cytokines 
(IL-4 and IL-lO) may produce a noninflammatory 
environment by down-regulating the immune re-
sponse to the allograft. promoting anergy and acceler-
ating graft acceptance. In these cases. tolerance can 
be maintained in a drug-free environment. 
We conclude that resumption of immunosuppres-
sion is not needed in some cases after life-threatening 
PTLD and HeV. This phenomenon may be more 
common in FK-506-treated liver recipients. The de-
velopment of a tolerant state may be related to an 
alteration of cytokine patterns. 
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